This is a working overview of Peptidomimetic, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-16. Anything still debated is marked as such rather than presented as settled.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
1993/1661) Immigration Appeals (Procedure) (Amendment) Rules 1993 (S.I. 1993/1662) Offshore Installations (Safety Zones) (No. 2) Order 1993 (S.I. 1993/1664) Recreation Grounds (Revocation of Parish Council Byelaws) Order 1993 (S.I. 1993/1665) Merchant Shipping (Fees) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/1676) Export of Goods (Control) (Haiti) Order 1993 (S.I. 1993/1677) Immigration (Transit Visa) Order 1993 (S.I. 1993/1678) Income Support (General) Amendment No. 3 Regulations 1993 (S.I. 1993/1679) Merchant Shipping (Prevention of Oil Pollution) (Amendment) Regulations 1993 (S.I. 1993/1680) Merchant Shipping (Prevention of Pollution by Garbage) (Amendment) Regulations 1993 (S.I. 1993/1681) Diseases of Animals (Seizure) Order 1993 (S.I. 1993/1685) Road Traffic Act 1991 (Commencement No. 6 and Transitional Provisions) (Amendment) Order 1993 (S.I. 1993/1686) Football Spectators Act 1989 (Commencement No. 4) Order 1993 (S.I. 1993/1690) Football Spectators (Designation of Football Matches in England and Wales) Order 1993 (S.I. 1993/1691) Export of Goods (Control) (Amendment No. 2) Order 1993 (S.I. 1993/1692) Road Traffic Offenders (Prescribed Devices) Order 1993 (S.I. 1993/1698)
Potassium alum is used in medicine mainly as an astringent (or styptic) and antiseptic. Styptic pencils are rods composed of potassium alum or aluminum sulfate, used topically to reduce bleeding in minor cuts (especially from shaving) and abrasions, nosebleeds, and hemorrhoids, and to relieve pain from stings and bites. Potassium alum blocks are rubbed over the wet skin after shaving. Potassium alum is also used topically to remove pimples and acne, and to cauterize aphthous ulcers in the mouth and canker sores, as it has a significant drying effect to the area and reduces the irritation felt at the site. It has been used to stop bleeding in cases of hemorrhagic cystitis and is used in some countries as a cure for hyperhidrosis. It is used in dentistry (especially in gingival retraction cords) because of its astringent and hemostatic properties. Potassium and ammonium alum are the active ingredients in some antiperspirants and deodorants, acting by inhibiting the growth of the bacteria responsible for body odor. Alum's antiperspirant and antibacterial properties contribute to its traditional use as an underarm deodorant. It has been used for this purpose in Europe, Mexico, Thailand (where it is called sarn-som), throughout Asia and in the Philippines (where it is called tawas). Today, potassium or ammonium alum is sold commercially for this purpose as a "deodorant crystal". Beginning in 2005 the US Food and Drug Administration no longer recognized it as a wetness reducer, but it is still available and used in several other countries, primarily in Asia.
=== Synthesis === Synthesis of RNA typically occurs in the cell nucleus and is usually catalyzed by an enzyme—RNA polymerase—using DNA as a template, a process known as transcription. Initiation of transcription begins with the binding of the enzyme to a promoter sequence in the DNA (usually found "upstream" of a gene). The DNA double helix is unwound by the helicase activity of the enzyme. The enzyme then progresses along the template strand in the 3' to 5' direction, synthesizing a complementary RNA molecule with elongation occurring in the 5' to 3' direction. The DNA sequence also dictates where termination of RNA synthesis will occur. Primary transcript RNAs are often modified by enzymes after transcription. For example, a poly(A) tail and a 5' cap are added to eukaryotic pre-mRNA and introns are removed by the spliceosome. There are also a number of RNA-dependent RNA polymerases that use RNA as their template for synthesis of a new strand of RNA. For instance, a number of RNA viruses (such as poliovirus) use this type of enzyme to replicate their genetic material. Also, RNA-dependent RNA polymerase is part of the RNA interference pathway in many organisms.
Throughout history there have been wars and conquests that were wide ranging, engulfing whole regions and beyond (so-called "central wars"), at times creating empires which spanned multiple continents, such as through the Mongol conquest. The creation of global maritime empires, as through European colonialism, has been characterized as global conquest, but only the wars between the resulting empires (so-called great powers) have been considered global wars, giving rise to a world wide understanding of conflict and war.
== Fisheries == Food and Agriculture Organization of the United Nations: In 2014, Thailand ranked number 14 in the world in "marine capture" of fish (harvesting of ocean species), 1.6 million tonnes, number 15 in "inland capture" (harvesting of fresh water species), 210,293 tonnesm, number 13 in "farmed species", 934,800 tonnes, and was the fourth leading exporter of fish, with exports valued at US$6.6 billion.
Sources: en.wikipedia.org
Referral to an out-patient genetics clinic (pediatric, adult, or combined) or an in-hospital consultation, most often for diagnostic evaluation. Specialty genetics clinics focusing on management of inborn errors of metabolism, skeletal dysplasia, or lysosomal storage diseases. Referral for counseling in a prenatal genetics clinic to discuss risks to the pregnancy (advanced maternal age, teratogen exposure, family history of a genetic disease), test results (abnormal maternal serum screen, abnormal ultrasound), and/or options for prenatal diagnosis (typically non-invasive prenatal screening, diagnostic amniocentesis or chorionic villus sampling). Multidisciplinary specialty clinics that include a clinical geneticist or genetic counselor (cancer genetics, cardiovascular genetics, craniofacial or cleft lip/palate, hearing loss clinics, muscular dystrophy/neurodegenerative disorder clinics).
=== Template-dependent DNA ligation === Template-dependent DNA ligation is a fragment-based oligonucleotide assembly method in which shorter, chemically synthesized oligonucleotide segments are aligned on a complementary nucleic acid template then joined through enzymatic ligation. This approach has been developed by a research group at Institute Pasteur and works as an alternative approach in order to overcome the length limitations of traditional methods. In one study, short oligonucleotide fragments, or ‘shortmers’, are designed to complement a given template strand, with correct positioning and orientation. DNA ligases can then be used to catalyze the formation of phosphodiester bonds between adjacent shortmers and create a continuous oligonucleotide strand. The incorporation of a template strand improves method specificity by promoting accurate base-pairing as well as reducing concatenation errors that occur during stepwise synthesis. Template-dependent ligation also enables the incorporation of chemically modified nucleotides, which can be more difficult using traditional synthesis techniques. As the individual shortmers are synthesized and purified prior to the assembly of the strand, the method allows for a reduction in cumulative yield loss and cumulative error compared to stepwise synthesis of long strands. These benefits push the method forward as a possible modular approach to construct longer and more complex oligonucleotides. Despite these advantages, template-dependent DNA ligation still has multiple limitations.
As expected from in vitro data, sertraline did not alter the human metabolism of the CYP3A4 substrates erythromycin, alprazolam, carbamazepine, clonazepam, and terfenadine; neither did it affect metabolism of the CYP1A2 substrate clozapine. Sertraline did not affect the actions of digoxin and atenolol, which are not metabolized in the liver. Case reports suggest that taking sertraline with phenytoin or zolpidem may induce sertraline metabolism and decrease its efficacy, and that taking sertraline with lamotrigine may increase the blood level of lamotrigine, possibly by inhibition of glucuronidation. CYP2C19 inhibitor esomeprazole increased sertraline concentrations in blood plasma by approximately 40%. Clinical reports indicate that interaction between sertraline and the MAOIs isocarboxazid and tranylcypromine may cause serotonin syndrome. In a placebo-controlled study in which sertraline was co-administered with lithium, 35% of the subjects experienced tremors, while none of those taking placebo did. Grapefruit should be avoided.
== History == 1919 F.D. Edwards establishes Edwards Equipment and Services in London, England. 1939 F.D. Edwards begins manufacturing vacuum equipment. 1955 The company acquires Alto Vuoto SpA, a freeze drying manufacturer in Italy. 1968 The company is acquired by BOC, after staying in private hands through the post-war period and until the 1960s when it went public. 1977 BOC Edwards acquire Kniese Apparatbau GmbH, a freeze drying manufacturer in Germany. 1992 Restructuring of Freeze Drying business resource centralised in Tonawanda (US). 1994 The company’s product portfolio is expanded with the acquisition of pharmaceutical filling systems from Calumatic in The Netherlands. 1995 The company’s portfolio is further expanded with loading systems introduced from the Dongen manufacturing site in The Netherlands. 2004 A joint venture is established with Tianli Cryogenic Company, a pharmaceutical freeze dryer manufacturer in Beijing, China. 2006 The BOC Group is acquired by Linde AG and together form The Linde Group. Linde sells the vacuum division of BOC Edwards. BOC Edwards Pharmaceutical Systems remains part of the Linde Group, as an independent division. 2008 IMA, Italy acquires the BOC Edwards Pharmaceutical Systems group creating IMA Edwards – a part of IMA Life division of the IMA group. 2010 Today the whole group has been renamed under the brand IMA LIFE - Aseptic Processing and Freeze Drying Solutions.
The rotation of plane polarized light by chiral substances was first observed by Jean-Baptiste Biot in 1812, and gained considerable importance in the sugar industry, analytical chemistry, and pharmaceuticals. Louis Pasteur deduced in 1848 that this phenomenon has a molecular basis. The term chirality itself was coined by Lord Kelvin in 1894. Individual enantiomers or diastereomers of a compound were formerly called optical isomers due to their distinct optical properties. At one time, chirality was thought to be restricted to organic chemistry, but this misconception was overthrown by the resolution of a purely inorganic compound, a cobalt complex called hexol, by Alfred Werner in 1911. In the early 1970s, various groups established that the human olfactory organ is capable of distinguishing chiral compounds.
Sources: en.wikipedia.org
Tellurium is a silvery-white shiny solid. It has a density of 6.24 g/cm3, is brittle, and is the softest of the commonly recognised metalloids, being marginally harder than sulfur. Large pieces of tellurium are stable in air. The finely powdered form is oxidized by air in the presence of moisture. Tellurium reacts with boiling water, or when freshly precipitated even at 50 °C, to give the dioxide and hydrogen: Te + 2 H2O → TeO2 + 2 H2. It reacts (to varying degrees) with nitric, sulfuric, and hydrochloric acids to give compounds such as the sulfoxide TeSO3 or tellurous acid H2TeO3, the basic nitrate (Te2O4H)+(NO3)−, or the oxide sulfate Te2O3(SO4). It dissolves in boiling alkalis, to give the tellurite and telluride: 3 Te + 6 KOH = K2TeO3 + 2 K2Te + 3 H2O, a reaction that proceeds or is reversible with increasing or decreasing temperature. At higher temperatures tellurium is sufficiently plastic to extrude. It melts at 449.51 °C. Crystalline tellurium has a structure consisting of parallel infinite spiral chains. The bonding between adjacent atoms in a chain is covalent, but there is evidence of a weak metallic interaction between the neighbouring atoms of different chains. Tellurium is a semiconductor with an electrical conductivity of around 1.0 S•cm−1 and a band gap of 0.32 to 0.38 eV. Liquid tellurium is a semiconductor, with an electrical conductivity, on melting, of around 1.9 × 103 S•cm−1. Superheated liquid tellurium is a metallic conductor. Most of the chemistry of tellurium is characteristic of a nonmetal. It shows some cationic behaviour.
== Display == While some of the tablets are being preserved for future study, some will be displayed in a museum exhibit entitled "London Mithraeum" located on the first two floors of the Bloomberg European Headquarters, which opened in November 2017.
Any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. (ICH E6) Sham therapy
Homozygous or compound heterozygous mutations are therefore likely subject to differential regulation depending on whether they are double missense, double truncating or mixed missense/truncating mutations. The homozygous Mybpc3-targeted knock-in mice, which genetically mimic the situation of severe neonatal cardiomyopathy are born without phenotype and soon after birth develop systolic dysfunction followed by (compensatory) cardiac hypertrophy. The human c.772G>A transition results in low levels of three different mutant Mybpc3 mRNAs and cMyBP-Cs in homozygous mice, suggesting a combination of haploinsufficiency and polypeptide poisoning as disease mechanism in the homozygous state. In addition, the combination of external stress (such as neurohumoral stress or aging) and Mybpc3 mutations have been shown to impair the UPS in mice, and proteasomal activities were also depressed in patients with hypertrophic cardiomyopathy or dilated cardiomyopathy. Skinned trabeculae or cardiac myocytes obtained from human patients carrying a MYBPC3 mutation or from heterozygous and homozygous Mybpc3-targeted knock-in mice exhibited higher myofilament Ca2+ sensitivity than controls. Disease-modeling by engineered heart tissue (EHT) technology with cardiac cells from heterozygous or homozygous Mybpc3-targeted knock-in mice reproduced observations made in human and mouse studies displaying abbreviated contractions, greater sensitivity to external Ca2+ and smaller inotropic responses to various drugs (isoprenaline, EMD 57033 and verapamil) compared to wild-type control EHTs.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.